|
Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection |
Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IA |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IA. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. Journal of Antimicrobial Chemotherapy 2014; 69(11): 2901-2912 Indexing Status Subject indexing assigned by NLM MeSH Aminoglycosides /economics /pharmacology /therapeutic use; Anti-Bacterial Agents /economics /pharmacology /therapeutic use; Clostridium Infections /drug therapy /economics; Clostridium difficile /drug effects; Cost-Benefit Analysis /methods; Humans; Markov Chains; Vancomycin /economics /pharmacology /therapeutic use AccessionNumber 22014031484 Date bibliographic record published 19/11/2014 |
|
|
|